Accelmed
Accelmed Partners is a private equity firm founded in 2009 that invests $20-100M+ in U.S. commercial-stage lower-middle-market HealthTech companies across medical devices, diagnostics, digital health, and tech-enabled services, managing over $630 million across two funds from offices in Aventura and Miami, Florida.
- Company typePrivate
- Founded2009
- HeadquartersAventura, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Accelmed does
Accelmed Partners is a private equity firm founded in 2009 by Dr. Uri Geiger with backing from Israeli healthcare entrepreneur Mori Arkin, originally operating as Accelmed Ventures (a $100M early-stage vehicle) before pivoting to a commercial-stage HealthTech buyout strategy with the launch of Accelmed Fund I, LP in 2016. The firm invests exclusively in U.S. commercial-stage lower-middle-market HealthTech companies with $20M-$70M revenues (control) or $10M+ (growth), deploying $20-100M+ per transaction across medical devices, tools & diagnostics, digital health, and tech-enabled healthcare services. Accelmed currently manages over $630 million of equity capital across two private equity funds, with Fund II closing at a $400 million hard cap in 2021 (more than 3x Fund I's $130M). The firm's revenue model is standard for private equity: recurring management fees on committed/invested capital plus performance-based carried interest (typically 20%) from successful exits, with the firm historically generating a 26.4% net IRR on Fund I (top quartile per PitchBook).
The firm operates a buy-and-build platform strategy, working closely with portfolio company management to improve operations, update product portfolios, and revamp commercial organizations, while executing add-on acquisitions to scale platform companies (e.g., Keystone Dental acquiring Osteon Medical; Veranex acquiring Medidee and Fusion Biotec; Bioness Medical acquiring Harmonic Bionics and the PoNS System). Accelmed sources deals through direct outreach and industry relationships, leveraging its Israeli roots for proprietary deal flow into U.S. markets, and exits via strategic acquisitions (Cogentix to Laborie for $240M, CartiHeal to Smith & Nephew for up to $330M, Trukera Medical to Bausch + Lomb) and SPAC mergers (Memic at over $1B equity value). The investment team of approximately 10-15 professionals combines PE transaction expertise with deep operating talent, including former Medtronic and FDA regulatory leadership, enabling active technical support across the portfolio.
Accelmed firmographics
Firmographics- Name
- Accelmed
- Legal name
- Accelmed Partners
- Website
- https://accelmed.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Accelmed Partners is a private equity firm founded in 2009 that invests $20-100M+ in U.S. commercial-stage lower-middle-market HealthTech companies across medical devices, diagnostics, digital health, and tech-enabled services, managing over $630 million across two funds from offices in Aventura and Miami, Florida.
- Ownership category
- akta.pro rank
Accelmed industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Services-Management Consulting Services (8742), Investment Advice (6282)
- akta.pro primary industry
- Education / EdTech Growth Equity (FSANACAL)
Keywords
Where Accelmed is headquartered
LocationHeadquarters
- HQ city
- Aventura
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Accelmed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Management Fees: Private equity fund management fees charged on committed capital to cover operational costs and fund management.
- Carried Interest: Performance-based carried interest from successful portfolio company exits, typically 20% of profits above hurdle rate.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Accelmed product offering
Product offeringCore offering
Accelmed is a private equity firm that makes control and growth investments in U.S. commercial-stage lower middle market HealthTech companies with revenues of $20-70M (control) or $10M+ (growth). The firm manages over $630 million across two private equity funds (Fund I at $130M and Fund II at $400M) plus the earlier $100M Accelmed Ventures vehicle, deploying $20-100M+ per company in medical devices, diagnostics, digital health, and tech-enabled services, and working closely with management teams on operational improvements and buy-and-build strategies.
Product overview
Accelmed is a private equity firm focused on acquiring and investing in commercial-stage HealthTech companies. The firm manages over $630 million across two private equity funds and maintains a portfolio of approximately 21 active portfolio companies spanning medical devices, tools & diagnostics, digital health, and tech-enabled services. Accelmed's portfolio includes notable companies such as Click Therapeutics (prescription digital therapeutics including CT-155 for schizophrenia, CT-132 for migraine, and Rejoyn for depression), Bioness Medical (advanced neuro rehabilitation technologies including FES systems and PoNS neuromodulation), GT Medical Technologies (GammaTile radiation therapy), NeuroPace (RNS System for epilepsy), MedMinder (connected pharmacy care), Acclaro Medical (aesthetic laser technology), Veranex (MedTech product development services), SKNV (dermatology digital health), Keystone Dental (dental implants), and AiCure (AI patient monitoring). The firm employs a private equity approach to health technology investing, working closely with management to improve operations, update product portfolios, and revamp commercial organizations.
Differentiator
Problem solved
Functional benefit
Products and services
- Accelmed Fund I, LP
- Accelmed Fund II, LP
- Accelmed Ventures
- Control and Growth Capital Investments
Quantifiable outcome
- 26.4% net IRR for Fund I (top quartile performance)
- +4 more outcomes
Companies that use Accelmed
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Accelmed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Accelmed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boehringer IngelheimcorePharmaceutical partner in Click Therapeutics' prescription digital therapeutic CT-155 for schizophrenia. Boehringer made $50M Series D strategic investment and transferred commercialization rights to Click. Ongoing collaboration on ENSPIRUS study completion.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Accelmed competitors and assessment
Company assessmentDirect peers
- H.I.G. BioHealth Partners: Healthcare-focused PE firm with ~$400M committed capital that co-led Accelmed's investment in Click Therapeutics. Directly comparable as a HealthTech-dedicated growth equity and buyout sponsor operating in similar deal-size band.
- Lauxera Capital Partners: HealthTech-focused investment firm based in Paris and San Francisco with a €260M vehicle that co-invested with Accelmed in Veranex. Closely comparable as a transatlantic HealthTech PE sponsor with similar sector focus.
- Longitude Capital: Healthcare-dedicated growth equity firm investing in commercial-stage medical device, biotech, and digital health companies. Comparable to Accelmed in sector focus, stage (commercial/growth), and transaction sizes.
- Patient Square Capital: Healthcare-focused PE firm making control and growth investments across medical devices, services, and pharmaceuticals. Comparable as a HealthTech-dedicated sponsor with a buy-and-build orientation similar to Accelmed.
- Avista Capital Partners: Healthcare-focused PE firm investing in middle-market medical device, pharmaceutical, and healthcare services companies. Comparable to Accelmed in sector specialization and middle-market deal-size focus.
- Linden Capital Partners: Healthcare-dedicated PE firm investing in middle-market companies across medical devices, specialty pharma, and services. Comparable to Accelmed in sector focus and lower middle market deal profile.
- Sofinnova Partners: European healthcare and life sciences specialist with growth and venture capital strategies. Comparable to Accelmed in HealthTech sector focus though typically investing at earlier stages and primarily in European assets.
- TVM Capital Healthcare: Healthcare-dedicated growth equity firm with US and Middle East operations. Comparable to Accelmed in healthcare specialization and growth-stage focus, with complementary geographic reach.
- Ampersand Capital Partners: Middle-market PE firm specializing in healthcare and life sciences. Comparable to Accelmed in healthcare-dedicated middle-market deal profile and growth equity orientation.
Regional players
- Gilde Healthcare: European healthcare specialist investing across medical devices, digital health, and therapeutics. Comparable to Accelmed in healthcare specialization but primarily serves European companies rather than the US lower middle market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Accelmed social profiles
Digital presenceAccelmed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accelmed leadership team
Management profileNumber of profiles
Profiles11 records
Accelmed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accelmed M&A and investment
M&A and investmentM&A4 records
Investments45 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accelmed
What does Accelmed do?
Accelmed is a private equity firm that makes control and growth investments in U.S. commercial-stage lower middle market HealthTech companies with revenues of $20-70M (control) or $10M+ (growth). The firm manages over $630 million across two private equity funds (Fund I at $130M and Fund II at $400M) plus the earlier $100M Accelmed Ventures vehicle, deploying $20-100M+ per company in medical devices, diagnostics, digital health, and tech-enabled services, and working closely with management teams on operational improvements and buy-and-build strategies.
Is Accelmed a public or private company?
Accelmed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Accelmed founded?
Accelmed was founded in 2009. It employs 11 to 50 people.
Where is Accelmed based?
Accelmed is headquartered in Aventura, United States, in the North America region.
How does Accelmed make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are Accelmed's main competitors?
Direct peers on record are H.I.G. BioHealth Partners, Lauxera Capital Partners, Longitude Capital, Patient Square Capital, Avista Capital Partners, Linden Capital Partners, Sofinnova Partners, TVM Capital Healthcare and Ampersand Capital Partners. Gilde Healthcare is listed as a regional player.
Does Accelmed have an API?
No public API is recorded for Accelmed.
What industry is Accelmed in?
Accelmed's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANACAL, Education / EdTech Growth Equity. Its NAICS code is 523940 and its SIC code is 8742.